CombiGene AB (publ) (COMBI.ST) Research

Headquartered in Lidingö, Sweden, CombiGene AB (publ) was established in 1999 and specializes in pioneering gene therapy solutions for severe, life-altering medical conditions. The company is currently advancing two primary gene therapy candidates in its pipeline. CG01, a treatment targeting epilepsy, is undergoing preclinical trials that include detailed biodistribution and toxicology assessments. Its second candidate, CGT2, is under development for addressing lipodystrophy. CombiGene also maintains strategic alliances, including a licensing and collaborative agreement with Lipigon Pharmaceuticals AB to create a gene therapy for partial lipodystrophy, and a partnership with Spark Therapeutics for the advancement of adeno-associated virus (AAV) based gene therapies.

Market snapshot

Symbol
COMBI.ST
Price
$2.47
Day change
-3.89%
Market cap
$46.1M
P/E ratio
-1.74x
52-week range
1.27-3.18
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Amniotics AB (publ) (AMNI.ST)
  • Cline Scientific AB (publ) (CLINE-B.ST)
  • Diagonal Bio AB (publ) (DIABIO.ST)
  • Emplicure AB (publ) (EMPLI.ST)
  • FRISQ Holding AB (publ) (FRISQ.ST)
  • Idogen AB (publ) (IDOGEN.ST)
  • Kancera AB (publ) (KAN.ST)
  • Pharmiva AB (publ) (PHARM.ST)

Open CombiGene AB (publ) (COMBI.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.